Blood cancer Patients' immune clues may predict COVID-19 risk
NCT ID NCT07204366
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 18 times
Summary
This study examines whether people with certain blood cancers (MPN) have autoantibodies that block a key immune protein called interferon. Researchers want to see how common these autoantibodies are and if they make COVID-19 more severe. About 219 participants will give a blood sample, but no treatment is given. The goal is to better understand why some MPN patients get very sick from COVID-19.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, 27100, Italy
Conditions
Explore the condition pages connected to this study.